Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Biogen Idec Inc. (BIIB)

-NasdaqGS
290.54 Down 0.94(0.32%) Apr 17, 4:00PM EDT
|After Hours : 289.99 Down 0.55 (0.19%) Apr 17, 7:58PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Biogen Idec Inc.
225 Binney Street
Cambridge, MA 02142
United States - Map
Phone: 781-464-2000
Website: http://www.biogenidec.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:6,850

Business Summary 

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company’s products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company’s Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Biogen Idec Inc.

Corporate Governance 
Biogen Idec Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 3. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 2; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. George A. Scangos Ph.D., 66
Chief Exec. Officer and Director
5.46M0.00
Mr. Paul J. Clancy , 52
Chief Financial Officer and Exec. VP of Fin.
1.38M1.43M
Mr. John G. Cox , 51
Exec. VP of Pharmaceutical Operations & Technology
1.17M0.00
Mr. Kenneth A. DiPietro , 55
Exec. VP of HR
1.45MN/A
Dr. Douglas Edward Williams Ph.D., 56
Exec. VP of R&D
1.48M0.00
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders